CEO & CIO
Ally Bridge Group
Frank is Founder, CEO and CIO of Ally Bridge Group (ABG), as a truly global multi-strategy and multi-stage life science-focused investment group with teams and offices in Hong Kong, New York and Europe and a portfolio of world-leading life science technologies with approximately US$3 billion in assets under management (mostly in life science). Under Frank’s leadership, among many investments, ABG initiated, led and completed the landmark US$3.3 billion take-private of Wuxi Pharmatech, a leading global life science services company, from NYSE in 2015 and; in 2018, led a US$300 million investment in California, US-based GRAIL, the world’s pioneer in early-stage cancer detection. ABG invests actively in medtech, biotech, and digital life science across various stages of the life cycle on a global basis.
Previously, Mr. Yu was Managing Director and Head of China Investments at Och-Ziff Capital Management (OZ), a leading global multi-strategy hedge fund, where he made some of OZ’s largest and highly successful investments. Prior to Och-Ziff, Mr. Yu was a Managing Director at Goldman Sachs in Hong Kong, where he headed several business units and led some of the most important restructuring, IPOs and M&A transactions in China. Before Goldman Sachs, Mr. Yu worked at Moody’s in New York, and then at Credit Suisse in London and Hong Kong where he was dedicated to risk management.